The gut peptide that rebuilds your intestine from the inside—how a single amino acid change turned a seven-minute hormone into a drug that gets patients off IV nutrition

GLP-2 and teduglutide represent the gold standard of peptide therapeutic development. The story begins with Daniel Drucker at the University of Toronto in 1996, who discovered that a 33-amino acid peptide produced by enteroendocrine L-cells in the lower intestine had a remarkable property: when administered to mice, it produced dramatic villus growth—taller intestinal projections, deeper crypts, more absorptive surface area. The gut was rebuilding itself in response to its own growth signal.

The translational challenge was pharmacokinetic. Native GLP-2 has a half-life of approximately seven minutes—dipeptidyl peptidase-4 (DPP-4) cleaves the second amino acid from the N-terminus almost immediately after release. The solution was a single substitution: replacing alanine at position 2 with glycine produced teduglutide, a DPP-4–resistant analog with a two-hour half-life. That one amino acid change made once-daily subcutaneous injection feasible and transformed a laboratory discovery into a drug.

Teduglutide (Gattex in the United States, Revestive in Europe) was approved by the FDA in December 2012 for adults with short bowel syndrome (SBS) who are dependent on parenteral support—intravenous nutrition delivered through a central line, often for 12 or more hours daily. The pivotal STEPS trial showed that 63% of teduglutide patients achieved at least 20% reduction in parenteral support volume, compared to 30% on placebo. Some patients achieved complete enteral autonomy—they came off IV nutrition entirely. For a population tethered to an infusion pump for daily survival, the clinical impact is transformative.

Quick Facts: GLP-2 at a Glance

What Is GLP-2 / Teduglutide?

Pronunciation: TED-oo-GLOO-tide

Your intestine has a remarkable capacity for self-renewal. The epithelial lining replaces itself every three to five days—one of the fastest tissue turnover rates in the body. This constant regeneration is coordinated by growth signals, and one of the most important is GLP-2: a 33-amino acid peptide released by cells in the lower intestine after you eat. GLP-2 tells the intestinal lining to grow—taller villi, deeper crypts, more absorptive surface. It is the gut's own growth hormone, directed inward.

Teduglutide is a pharmaceutical version of GLP-2 engineered to last long enough to be useful. Native GLP-2 is destroyed by the enzyme DPP-4 within about seven minutes of entering the bloodstream—far too fast for a therapeutic drug. Researchers at NPS Pharmaceuticals replaced a single amino acid at position 2 (alanine to glycine), which prevents DPP-4 from recognizing and cleaving the peptide. The result: a half-life of approximately two hours, making once-daily injection practical.

The clinical target is short bowel syndrome (SBS)—a condition in which surgical removal of large portions of the small intestine (due to Crohn's disease, mesenteric ischemia, trauma, or neonatal conditions) leaves patients unable to absorb enough nutrients from food. These patients depend on parenteral nutrition: IV solutions of amino acids, glucose, lipids, electrolytes, and vitamins delivered through a central venous catheter, typically for 12 or more hours daily. The central line carries infection risk. The infusion schedule dominates daily life. Liver damage from chronic parenteral nutrition is a long-term concern. For these patients, any reduction in IV dependence is clinically meaningful.

Teduglutide rebuilds the remaining intestine's absorptive capacity—taller villi mean more surface area, and more surface area means more nutrient absorption from food.

Origins and Discovery

The GLP-2 story begins with proglucagon—a large precursor protein that is sliced into different peptide products depending on where in the body the slicing occurs. In the pancreas, proglucagon processing produces glucagon. In the intestine and brain, the same protein produces GLP-1 (the incretin hormone that spawned semaglutide and tirzepatide) and GLP-2 (the intestinotrophic peptide). GLP-1 and GLP-2 are molecular siblings—born from the same parent molecule, released from the same cells, secreted at the same time after a meal, but with entirely different biological functions.

GLP-1 was the early star. Its role in insulin secretion and glucose regulation was recognized first, and GLP-1 receptor agonists became one of the most commercially successful drug classes in history. GLP-2 was identified at the same time but remained poorly understood—its receptor was not cloned until 1999, and its biology was not characterized until Drucker's landmark experiments.

In 1996, Daniel Drucker's group at the University of Toronto administered GLP-2 to mice and observed dramatic intestinal growth—increased villus height, increased crypt depth, increased intestinal weight. The finding was startling in its magnitude: the gut was not just maintaining itself, it was actively rebuilding under GLP-2 stimulation. Drucker recognized the therapeutic implication immediately—patients with shortened intestines could potentially regrow absorptive surface.

The DPP-4 problem was already familiar from GLP-1 drug development. Native GLP-2, like GLP-1, is cleaved at position 2 by DPP-4 within minutes. The Ala2→Gly substitution—the same strategy that had been explored for GLP-1 analogs—produced teduglutide, which resisted DPP-4 degradation and extended the half-life to approximately two hours.

NPS Pharmaceuticals developed teduglutide through clinical trials for SBS. The company was later acquired by Shire, which was acquired by Takeda. Throughout these corporate transitions, teduglutide's development continued, resulting in FDA approval in December 2012 for adults and 2019 for pediatric patients (ages 1 and older).

Mechanism of Action

GLP-2 Receptor Signaling

The GLP-2 receptor (GLP-2R) is a class B GPCR expressed on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells in the intestinal wall. Critically, GLP-2R is NOT expressed on intestinal epithelial cells themselves—the cells that actually proliferate and form the absorptive surface. This means GLP-2's trophic effect is indirect, mediated through paracrine signaling from receptor-bearing cells to adjacent epithelial cells.

GLP-2R activation triggers the Gαs signaling cascade: adenylyl cyclase → cAMP → protein kinase A. This produces release of downstream growth factors from the receptor-bearing cells—primarily insulin-like growth factor-1 (IGF-1) from subepithelial myofibroblasts, along with epidermal growth factor (EGF) and keratinocyte growth factor (KGF). These growth factors then stimulate the intestinal epithelial stem cells in the crypts to proliferate, driving crypt cell division → villus growth → increased absorptive surface area.

Intestinal Adaptation

The intestine's response to teduglutide mirrors the natural adaptation process that occurs after intestinal resection. When a section of intestine is removed, the remaining bowel gradually increases its absorptive capacity—villi grow taller, crypts deepen, and the remaining epithelium becomes more efficient at nutrient transport. This adaptation is partly mediated by endogenous GLP-2 from L-cells in the remaining ileum and colon.

Teduglutide amplifies and accelerates this adaptation in patients whose remaining bowel has reached the limits of natural compensation. The drug does not create new intestine—it enhances the absorptive capacity of the intestine that remains.

The specific structural changes include: increased villus height (more absorptive surface per unit length of intestine), increased crypt depth (larger stem cell compartment supporting faster epithelial renewal), enhanced nutrient transporter expression on the villus surface, and improved blood flow to the remaining intestine (teduglutide increases mesenteric blood flow, facilitating nutrient transport from the lumen to the bloodstream).

Barrier Function Enhancement

GLP-2 signaling strengthens tight junctions between intestinal epithelial cells, reducing paracellular permeability. This improves barrier function—reducing bacterial translocation and supporting immune homeostasis. The barrier effect is distinct from the trophic effect and may contribute to GLP-2's anti-inflammatory properties observed in preclinical IBD models.

The DPP-4 Engineering Solution

Native GLP-2 has an alanine at position 2 that DPP-4 recognizes and cleaves, releasing a dipeptide from the N-terminus and inactivating the hormone within approximately seven minutes. Teduglutide replaces this alanine with glycine—a smaller amino acid that DPP-4 cannot efficiently bind and cleave. The result is a half-life extension from ~7 minutes to ~2 hours, a roughly 17-fold improvement that makes once-daily subcutaneous injection therapeutically viable.

This engineering approach—making a single amino acid change to evade DPP-4—is the same strategy that underpins GLP-1 drug development. Native GLP-1 also has a ~2-minute half-life due to DPP-4. Exenatide, liraglutide, and semaglutide all incorporate modifications to resist DPP-4 cleavage, though their strategies differ (fatty acid acylation for liraglutide, albumin binding for semaglutide). Teduglutide's approach is the simplest—one amino acid, one substitution, problem solved.

Key Research Areas and Studies

STEPS Trial—The Pivotal Study (2012, PMID 22612591)

The Study of Teduglutide Effectiveness in Parenteral nutrition–dependent Short bowel syndrome (STEPS) was the Phase 3 trial that led to FDA approval.

Design: Randomized 2:1, double-blind, placebo-controlled. N=86 adults with SBS dependent on parenteral support (PS) for at least 12 months. Teduglutide 0.05 mg/kg SC once daily vs. placebo. 24-week treatment period.

Primary endpoint: Proportion of patients achieving at least 20% reduction in weekly PS volume at week 24.

Results: 63% of teduglutide patients achieved the primary endpoint vs. 30% of placebo patients (p=0.002). Mean PS volume reduction: 4.4 L/week (teduglutide) vs. 2.3 L/week (placebo). The clinical significance is substantial—a 4.4 L/week reduction translates to approximately one fewer day per week on IV nutrition for many patients.

STEPS-2—Long-Term Extension (2013, PMID 23612385)

Design: Open-label extension of STEPS. Patients who completed STEPS could continue teduglutide for up to 30 months total.

Results: PS volume reductions were sustained and, in many patients, continued to improve over time. Some patients achieved complete enteral autonomy—they came off parenteral support entirely. This demonstrated that the intestinal adaptation driven by teduglutide is durable and progressive.

STEPS-3—Multi-Year Follow-Up (PMID 27631491)

Further long-term extension data confirmed sustained efficacy and safety over years of continuous teduglutide treatment. No loss of effect was observed—the intestinal adaptation achieved early in treatment persisted.

Pediatric SBS (2019, PMID 30825399)

Design: Phase 3 RCT in children with SBS (ages 1–17). Teduglutide 0.05 mg/kg SC once daily vs. standard of care.

Results: Teduglutide significantly reduced PS volume in pediatric patients. The results led to FDA pediatric approval in 2019 for children ages 1 and older.

The pediatric indication is particularly important because many SBS cases originate in neonates—necrotizing enterocolitis, intestinal atresia, midgut volvulus—and these patients may face a lifetime of parenteral nutrition dependence without intestinal adaptation.

Crohn's Disease (2005, PMID 16508634)

Design: Phase 2 RCT. N=100 patients with active Crohn's disease. Teduglutide vs. placebo.

Results: Trend toward clinical remission but the primary endpoint was not met. The mucosal healing effect was suggestive but insufficient for regulatory advancement.

Significance: This was an attempt to extend GLP-2's intestinotrophic biology to inflammatory bowel disease, where mucosal healing is a therapeutic goal. The negative result limits but does not eliminate the GLP-2/IBD hypothesis—the trial may have been underpowered, and the Crohn's population may need longer treatment duration for mucosal effects to manifest.

Claims vs. Evidence

The Human Evidence Landscape

STEPS Phase 3 (2012, PMID 22612591)

Design: Randomized 2:1, double-blind, placebo-controlled. N=86 adults with SBS on PS for ≥12 months.

Findings: Primary endpoint met: 63% of teduglutide patients achieved ≥20% PS volume reduction vs. 30% placebo (p=0.002). Mean PS reduction: 4.4 L/week vs. 2.3 L/week. Response was consistent across SBS etiologies (Crohn's, mesenteric ischemia, other surgical causes).

Limitations: Relatively small sample (N=86), reflecting the orphan disease population. 2:1 randomization meant only ~29 patients on placebo. The 24-week treatment period may underestimate long-term response, given extension data showing progressive improvement.

STEPS-2 Extension (2013, PMID 23612385)

Design: Open-label extension. N=65 patients continuing from STEPS.

Findings: PS volume reductions sustained at 30 months. Progressive improvement in some patients. Multiple patients achieved complete enteral autonomy (100% PS elimination). No loss of efficacy over time—the intestinal adaptation was durable.

Limitations: Open-label design after the initial 24-week blinded period. No placebo comparator for the extension phase. Selection bias (patients who benefited most may have been more likely to continue).

STEPS-3 Multi-Year Data (PMID 27631491)

Further extension demonstrated sustained efficacy and safety over years of treatment. No new safety signals. The polyp surveillance requirement (colonoscopy before initiation and periodically during treatment) was maintained.

Pediatric Phase 3 (2019, PMID 30825399)

Design: Randomized, controlled. N=59 children (ages 1–17) with SBS on PS. Teduglutide 0.05 mg/kg SC daily vs. standard of care.

Findings: Significant PS volume reduction in the teduglutide group. Growth and development outcomes were also assessed—no adverse developmental effects. Led to pediatric label expansion (2019).

Limitations: Smaller sample reflecting the pediatric orphan population. Comparison to standard of care rather than strict placebo (ethical considerations in denying an approved therapy to children).

Crohn's Disease Phase 2 (2005, PMID 16508634)

Design: RCT. N=100 adults with active Crohn's disease. Teduglutide vs. placebo.

Findings: Trend toward clinical remission (CDAI reduction) but primary endpoint not met. Some mucosal healing signals. The study was described as "exploratory" and teduglutide was not pursued further for IBD.

Real-World Evidence

Multiple registry studies and single-center retrospective analyses from SBS treatment centers confirm PS reduction rates consistent with clinical trial data. Real-world enteral autonomy rates (patients completely off PS) have been reported in the 20–30% range with prolonged treatment—consistent with and slightly lower than trial data, as expected in unselected populations.

Safety, Risks, and Limitations

Clinical Trial and Post-Marketing Safety

Injection site reactions: ~25%. The most common adverse event. Typically mild—redness, swelling, or tenderness at the injection site. Usually diminish with continued use.

Abdominal pain: ~20%. Expected given the intestinotrophic mechanism—the gut is actively growing and adapting. Typically manageable and does not require discontinuation.

Nausea, vomiting: ~15%. More common in the first weeks of treatment and tends to diminish over time.

Intestinal Polyps—The Primary Safety Concern

Polyp incidence in clinical trials: ~2%. Intestinal polyps were detected in a small proportion of teduglutide-treated patients during surveillance colonoscopy.

The concern is mechanistically rational. Teduglutide's entire purpose is stimulating intestinal epithelial proliferation—taller villi and deeper crypts mean more rapidly dividing cells. Any growth-promoting agent carries theoretical risk that proliferation could become dysregulated, progressing from normal growth to polyp to neoplasia.

The current evidence is reassuring but warrants continued vigilance. No confirmed malignancy signal has emerged from clinical trials or post-marketing surveillance. However, the total patient-years of exposure are still limited relative to the latency period for colorectal neoplasia. The REMS program requiring colonoscopy surveillance reflects this appropriate caution.

Other Safety Considerations

Fluid balance: As patients reduce PS, oral fluid management becomes critical. Rapid PS reduction without compensating oral intake can lead to dehydration and electrolyte imbalances. Dose titration of parenteral support should be gradual and clinician-supervised.

Gallbladder/biliary events: Gallstones and cholecystitis have been reported during teduglutide treatment. The mechanism may relate to changes in bile flow and composition as intestinal adaptation alters enterohepatic circulation.

Catheter complications: SBS patients on PS have central venous catheters, which carry ongoing infection risk. Catheter-related complications are common in this population regardless of teduglutide use. Reducing PS days may ultimately reduce catheter-related complications by reducing central line dwell time.

Limitations

Orphan disease only. Teduglutide is approved exclusively for SBS with PS dependence. The drug is not indicated, tested, or appropriate for general gut health, IBD, leaky gut, or any non-SBS intestinal condition.

Specialty pharmacy only. Teduglutide is distributed through a restricted REMS program (iPAS). It is not available through retail pharmacies, research peptide vendors, or compounding pharmacies.

Does not regenerate removed intestine. Teduglutide enhances the absorptive capacity of remaining intestine through epithelial adaptation (taller villi, deeper crypts). It does not create new intestinal segments to replace surgically removed bowel.

Cost. Teduglutide is a specialty biologic priced for an orphan disease population. Annual cost is substantial—though cost-effectiveness analyses suggest savings from reduced PS requirements, hospital admissions, and catheter-related complications can partially offset the drug cost.

Legal and Regulatory Status

FDA Status

Teduglutide (Gattex, Takeda) is FDA-approved for: - Adults with short bowel syndrome who are dependent on parenteral support (2012) - Pediatric patients ages 1 year and older with SBS who are dependent on parenteral support (2019)

Orphan drug designation. Distributed through the iPAS REMS program requiring colonoscopy surveillance.

EMA Status

Teduglutide (Revestive, Takeda) approved 2012 for SBS in adults requiring parenteral support. European pediatric approval followed.

WADA Status

Teduglutide is not on the WADA Prohibited List.

Prescription and Distribution

Specialty pharmacy only. REMS program. Not available through research chemical vendors, compounding pharmacies, or any non-prescription channel.

Research Protocols and Formulation Considerations

Formulation

Gattex (teduglutide) is supplied as a sterile, lyophilized powder in single-use vials (5 mg per vial). Reconstituted with 0.5 mL of the provided prefilled diluent syringe (sterile water for injection, preserved with 0.9% benzyl alcohol) to yield a concentration of 10 mg/mL.

Note: The benzyl alcohol preservative means the pediatric formulation for neonates (under 1 month) is not recommended—benzyl alcohol has been associated with neonatal toxicity (gasping syndrome).

Storage

Unreconstituted vials: 2–8°C (36–46°F). Reconstituted solution: use within 3 hours. Do not freeze.

Administration

Subcutaneous injection, once daily, alternating injection sites (abdomen, thighs, upper arms). Patients or caregivers are trained on self-injection technique. No IV administration.

Dosing in Published Research

The following table summarizes dosing protocols for GLP-2 as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

FDA-Approved Dosing

Clinical Trial Dosing

The dose has been consistent across all trials—0.05 mg/kg SC daily. The Crohn's trial also tested 0.10 mg/kg, but higher doses did not show greater efficacy and were associated with more adverse events.

Dosing in Self-Experimentation Communities

Teduglutide has no self-experimentation community. The drug is a specialty biologic for an orphan disease (SBS), distributed exclusively through a REMS program requiring prescriber certification, colonoscopy surveillance, and specialty pharmacy dispensing. It is not available from research peptide vendors, compounding pharmacies, or any non-prescription source.

Native GLP-2 (the unmodified endogenous peptide) is available from some research peptide vendors, but its 7-minute half-life makes any self-administration protocol biologically impractical—the peptide would be cleared before meaningful receptor activation could occur.

The community interest in gut health peptides is centered on BPC-157, which has a completely different mechanism (cytoprotective, not intestinotrophic) and a completely different evidence base (preclinical vs. FDA-approved). GLP-2/teduglutide and BPC-157 are not comparable or interchangeable.

Combination Stacks

Research into GLP-2 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining GLP-2 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

GLP-2/teduglutide represents peptide therapeutics at their most precise: an endogenous intestinal growth signal, identified through rigorous basic science, engineered with a single amino acid change to solve a specific pharmacokinetic problem, and applied to a specific disease where that growth signal is exactly what is missing. The STEPS trial demonstrated clear clinical benefit (63% response rate) with a meaningful endpoint (reduced IV nutrition dependence). Long-term extensions showed sustained and progressive improvement. Pediatric approval extended the benefit to children born with devastating intestinal conditions.

The drug's safety profile is favorable, with the intellectually honest caveat that a growth-promoting peptide requires ongoing polyp surveillance. The absence of a malignancy signal through years of follow-up is reassuring; the requirement for colonoscopy is appropriate.

For Peptidings, teduglutide is the Cluster I exemplar—the compound that demonstrates what gut peptide biology can achieve when the science, the drug design, and the clinical development are all done right. Alongside secretin (the diagnostic pioneer) and CCK (the diagnostic workhorse), teduglutide completes a trio that shows the full spectrum of peptide clinical utility—from provoking a diagnostic response to rebuilding an organ.

Verdict Recapitulation

FDA-approved for adults (2012) and children (2019). Phase 3 RCT with clinically meaningful primary endpoint (PS volume reduction). Multi-year extension data showing sustained efficacy and enteral autonomy achievement. Clear mechanism, elegant drug design, genuine clinical impact in a devastating orphan disease. The colonoscopy surveillance requirement reflects appropriate caution for a growth-promoting agent—not a safety failure. This is peptide therapeutics working exactly as intended.

For readers considering GLP-2, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source GLP-2

Further Reading and Resources

If you want to go deeper on GLP-2, the evidence landscape for gut health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Gut Health Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: GLP-2 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. (2012). "Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome." Gut, 61(7), 1013–1023. PMID 22612591
2. Jeppesen PB, Pertkiewicz M, Messing B, et al. (2012). "Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure." Gastroenterology, 143(6), 1473–1481.e3. PMID 23612385
3. Schwartz LK, O'Keefe SJD, Fujioka K, et al. (2016). "Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome." Clinical and Translational Gastroenterology, 7(2), e142. PMID 27631491
4. Kocoshis SA, Merritt RJ, Hill S, et al. (2020). "Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: a 24-week, randomized, multicenter study." Journal of Pediatric Gastroenterology and Nutrition, 70(3), 348–355. PMID 30825399
5. Drucker DJ, Erlich P, Asa SL, Brubaker PL. (1996). "Induction of intestinal epithelial proliferation by glucagon-like peptide 2." Proceedings of the National Academy of Sciences, 93(15), 7911–7916. PMID 8755576
6. Buchman AL, Katz S, Fang JC, et al. (2010). "Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease." Inflammatory Bowel Diseases, 16(6), 962–973. PMID 16508634
7. Drucker DJ, Yusta B. (2014). "Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2." Annual Review of Physiology, 76, 561–583. PMID 24215944
8. Burness CB, McCormack PL. (2013). "Teduglutide: a review of its use in the treatment of patients with short bowel syndrome." Drugs, 73(9), 935–947. PMID 23729001
9. Jeppesen PB. (2012). "Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome." Therapeutic Advances in Gastroenterology, 5(3), 159–171. PMID 22570677
10. Sigalet DL, de Heuvel E, Wallace L, et al. (2020). "Effects of chronic glucagon-like peptide-2 exposure on intestinal morphology, function, and fluid and electrolyte balance in juvenile pigs." American Journal of Physiology-Gastrointestinal and Liver Physiology, 318(4), G555–G564

---